Abstract:Background: Despite the potential for tumor-specific T cells to mediate durable complete responses, even in advanced disease, no CAR-T cell treatment is currently approved for use against any solid cancers [1–3]. While a large majority of solid cancers express tumor-associated antigens (TAAs) that are vulnerable to CAR T cell recognition, in nearly all cases TAAs are present in healthy tissues [4]. Since CAR T cells cannot differentiate between cancer and normal cells, CAR T cell recognition of TAAs on healthy tissues provokes dose-limiting 'on-target off-tumor' toxicities at sites of endogenous expression, most commonly the lungs [5–8]. Metastatic patterns of solid cancer are heterogenous, and in some cases lethal disease is limited to a single organ throughout a patient's entire disease course – i.e. oligometastasis. For example, the liver is the sole site of metastasis in approximately 20,000 colorectal cancer deaths per year in the United States and the most common site of visceral metastasis from solid cancer overall [9–11]. We sought to capitalize on the oligometastatic biology of some cancers by genetically encoding CAR-T cells to restrict their activity to the cancer involved-organ while limiting CAR-T cell trafficking and associated toxicity to non-cancer sites. Methods: We develop two immunocompetent murine models of CAR T cell transfer targeting TAAs abundant in metastatic colorectal cancer and pancreatic cancer (EpCAM and CEA). Conventional TAA-specific CAR T cells affected tumor shrinkage but also infiltrated and damaged non-cancerous organs that expressed the TAA (lung, pancreas, & colon) [12]. The respiratory system was the site of greatest pathology in both models, with massive CAR T cell accumulation and tissue destruction, resulting in dose-limiting lethality. To mitigate off-tumor toxicity, we developed a multiparameter genetically encoded program that leverages endogenous chemokine and tissue resident systems to imbue CAR-T cells with liver tropism and enhanced functionality (Figure 1). Results: Liver-directed programming of CAR T cells in both CEA and EpCAM CAR models resulted in highly preferential trafficking of CAR T cells to liver tumors and limited CAR T cell trafficking and toxicity in non-cancerous tissues that share expression of the tumor associated antigen. Conclusions: Organ-directed targeting of TAA specific CAR-T cells is a promising approach to treat oligo-metastatic disease while avoiding off-tumor toxicities. Based on these results we are preparing to initiate phase 1b clinical (3+3) trial using liver-directed CEA specific CAR T cells in patients with colorectal liver metastasis. Citation Format: Alexandra Bartlett, Robert MD Eil. A novel approach and model to limit cytokine release syndrome and off-tumor toxicity of synthetically enhanced CEA CAR-T cells [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr B050.

CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids

CEA expression patterns determine response and resistance to the CEA-TCB bispecific immunotherapy antibody in colorectal cancer patient derived organoids.

The CEA-/lo colorectal cancer cell population harbors cancer stem cells and metastatic cells.

Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers

Optimizing the design and geometry of T cell engaging bispecific antibodies targeting CEA in colorectal cancer

CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC).

Association of B Cells in Tumor Microenvironment (TME) with Clinical Benefit to Programmed Cell Death Protein-1 (PD-1) Blockade Therapy in Esophageal Squamous Cell Carcinoma (ESCC).

Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine

Next-Generation CEA-CAR-NK-92 Cells against Solid Tumors: Overcoming Tumor Microenvironment Challenges in Colorectal Cancer

Abstract 243: Organoid co-cultures with allogenic T cells to assess toxicity and efficacy of bispecific antibodies

Abstract B050: A novel approach and model to limit cytokine release syndrome and off-tumor toxicity of synthetically enhanced CEA CAR-T cells

Epidermal Growth Factor Receptor Targeting in Colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance

Colorectal cancer patients-derived immunity-organoid platform unveils cancer-specific tissue markers associated with immunotherapy resistance

Abstract 6357: Establishing a reverse translational platform to dissect mode of action and mechanisms of resistance to GUCY2C-CD3 T cell engager

Tumor Growth Suppression of Pancreatic Cancer Orthotopic Xenograft Model by CEA-Targeting CAR-T Cells

Abstract LB091: Design, characterization and preclinical validation of a combinatorial CAR-based immunotherapy against colorectal cancer with HER2 amplification

Characterization of a Novel T Cell-Engaging Bispecific Antibody for Elimination of L1CAM-positive Tumors

Abstract 6340: Novel conditionally active tetravalent B7-H3 x CD3 T-cell engagers targeting solid tumors

Suppression of Murine Colitis and its Associated Cancer by Carcinoembryonic Antigen-Specific Regulatory T Cells

Abstract 1868: Target-dependent considerations for the design of bispecific T-cell engagers